ÍøºìºÚÁÏ

Skip to main content
(352) 273-8740

Jorge E Lascano, MD

Critical Care Specialist

Photo of Jorge E Lascano
(352) 273-8740 MyUFÍøºìºÚÁÏ

Research at a glance

Top areas of exploration

  • alpha 1-Antitrypsin Deficiency , 9 publications
  • Pulmonary Disease, Chronic Obstructive , 8 publications
  • alpha 1-Antitrypsin , 7 publications
  • Cystic Fibrosis , 3 publications

Research activity

44 publications

427 citations

Why is this important?

Active clinical trials

Serpentine-1

The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency…

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - 70 Years
Sexes
All
KB407-02

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
ELEVAATE OLE

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - 80 Years
Sexes
All

My publications

44 publications

2021

Gender and racial disparities in lung transplantation in the United States.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

•

2021

Post-transplant patients with COVID-19 associated acute respiratory distress syndrome, a role for Tociluzumab: A case series.

Respiratory medicine case reports

•

2020

Clinical outcomes and survival following lung transplantation in patients with Alpha-1 antitrypsin deficiency.

Respiratory medicine

•

2020

Disseminated Nocardia beijingensis Masquerading as Pulmonary Tuberculosis in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome.

Open forum infectious diseases

•

2020

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial.

PloS one

•